X-Linked Hypophosphatemia Transition and Team Management

Kubota, Takuo

doi:10.3390/endocrines3030032

Cited by 2 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…XLH is usually diagnosed by a paediatrician or paediatric endocrinologist [57]. Knowledge and treatment of XLH is generally limited to specialist centres, with the condition demanding care from multidisciplinary teams [29], including endocrinologists, nephrologists and geneticists [58]. Furthermore, burosumab is increasingly becoming the standard of care, evidenced by its reimbursement in many European countries and its approval for use in children prior to reaching the end of skeletal growth [28,29].…”

Section: Data Analysesmentioning

confidence: 99%

A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia (XLH)

Saraff,

Boot,

Linglart

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

The importance of patient centricity and keeping the patient at the heart of research design is now well recognised within the healthcare community. The involvement of patient, caregiver and clinician representatives in the study design process may help researchers to achieve this goal and to ensure robust and meaningful data generation. Real-world data collection allows for a more flexible and patient-centred research approach for gaining important insights into the experience of disease and treatments, which is acutely relevant for rare diseases where knowledge about the disease is more likely to be limited. Here, we describe a practical example of a patient-centric, multi-stakeholder approach that led to the co-design of a prospective observational study investigating the lived experience of adolescents with the rare disease, X-linked hypophosphataemia. Specifically, we describe how the knowledge and expertise of a diverse research team, which included expert physicians, research and technology specialists, patients and caregivers, were applied in order to identify the relevant research questions and to ensure the robustness of the study design and its appropriateness to the population of interest within the context of the current clinical landscape. We also demonstrate how a structured patient engagement exercise was key to informing the selection of appropriate outcome measures, data sources, timing of data collection, and to assessing the feasibility and acceptability of the proposed data collection approach.

show abstract